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FIGURE 7. Volume of surgical and percutaneousmitral valve treatment at
the University Heart Center Hamburg 2002–2010.
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Dregurgitation, the need for less-invasive mitral valve thera-
pies is evident. Interventional cardiologists and cardiac
surgeons as a heart team have the knowledge and under-
standing of mitral valve pathology and repair techniques.
It seems only natural that any technique of interventional
MVR should be performed in close collaboration and after
detailed discussion among the heart team. As members of
the team, cardiac surgeons should now consequently take
the chance to adopt these new techniques and make them
part of their portfolio.References
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Dr A. Marc Gillinov (Cleveland, Ohio). That was an excellent
and timely article. You present results in 202 patients receiving the
MitraClip device. Your 30-day mortality was only 1%. The mean
decrease inMR gradewith the procedurewas 1.7, and, remarkably,
at 1 year, 72% of surviving patients are in functional class I or II.
So I will ask you 3 fairly straightforward questions, that is, who,
how, and when.
First is the who question, and that is the most important. You
have described the patients who are treated, who they are, and
how you get to them. It looked to me from the article, which
you were kind enough to provide, that it tends to be people with
functional MR who have often undergone previous cardiac sur-
gery. My main question with ‘‘who,’’ though, is this: As your ex-
perience has increased and you have developed a greater comfort
zone, are you seeing the indications creep into the surgical popu-
lation? Are you seeing more patients in whom you would say,
we could operate on him, but let’s try percutaneous first?
Dr Treede. Actually, that is not the case. We do not switch our
indications. We still perform surgery in all patients who are oper-
able, and we have no reason to change this unless the results of sur-
gery are still better than the results of the MitraClip therapy in
terms of reduction ofMR, and becausewe know the data published
by Sarano and colleagues that patients with remaining MR 2+
don’t do as well in the long-term follow-up compared with patients
without MR. So this should be the reason not to switch indications.
Especially in patients with organic MR, myxomatous disease, or
even Barlow valves, the MitraClip device will probably come to
its limits.
Dr Gillinov. The second question is how, not how do you do the
procedure, but how should we judge success of the procedure?
There seem to be 2 ways in which people judge the percutaneous
repair. One is, how did we do with the MR, and the other is, how
are the patients doing in terms of with functional class? For the
MR, you declare procedural success if the MR is 2+ or less, but
I note that at 1 year, only 28% of patients have MR that is 1+ or
less (a surgical success). That doesn’t sound very good. But, on
the other hand, with approximately three quarters in NYHA class
I or II, you could say the procedure is successful for the patient.
How should we judge success?
Dr Treede. I would still suggest that we judge success by the
grade of MR, because NYHA class is a subjective thing, and it
is dependent on other variables (eg, medical therapy) that are not
this measurable. So if we clearly stick to the echo data, we will
find out what proportion the MitraClip therapy has on that better
functional result. So I would still do that, although it is not thisardiovascular Surgery c Volume 143, Number 1 83
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Deasy to judge MR after MitraClip therapy, because the double or-
ifice may complicate echo measurements.
Dr Gillinov. The final question is when. When should we oper-
ate if the clip has not worked? Clearly you get scar tissue and in-
growth, and the surgical repair will be more challenging months
down the road. Given what you know now, would you recommend
to us to operate early if the patient leaves the catheter laboratory
with 3+ MR?
Dr Treede. Yes, we have seen that it is harder to get the clip out
once it is really ingrown into the valve. On the other hand, I would
still make the decision dependent on the degree of MR, and I
would not prophylactically operate on a patient who does not
have severe regurgitation after the clip treatment. But once you
have a severe regurgitation and the clip did fail, then it is definitely
easier to do the operation earlier.
Dr Gillinov. Thank you. That was excellent.
Dr Gorav Ailawadi (Charlottesville, Va). I commend you on
doing this important study. Can you give us more insight on those
11 patients who required a mitral operation as to the number of
clips that were inserted and if that affected the ability to repair
the valve? What was the risk in those 11 patients? You mention
an 18% mortality. Do you have an idea of what their euroSCORE
or Society of Thoracic Surgeons’ risk was before determining
placement of a MitraClip device?
Dr Treede. These were all in patients with a high euroSCORE,
but as you know, a high euroSCORE does not mean that they are,
by definition, inoperable, so we were able do the operations. Un-
fortunately, we do not have too much information on those patients
who died after surgery, because they died in outside hospitals.
We cannot say with regard to the small numbers right now if the
number of clips has any influence on the surgical outcome. One
can, of course, assume that more clips would probably do more
harm to the mitral valve, but having operated on some of themmy-
self, I can say that the injury that the clip leaves at the leaflets is, in84 The Journal of Thoracic and Cardiovascular Surgemost cases, not so harmful that the valve is no longer repairable. So
I cannot answer this part of the question right now.
Dr Robert Dion (Genk, Belgium). I am impressed by your pio-
neering work, but I have a few questions. First, you evaluate the
results by considering the amount of residual MR or the NYHA
class. But what about the remodeling of the left ventricle (the di-
mensions and volumes), how did it evolve with the time? Indeed,
in principal, I have an objection to call a success a residual grade 2
MR in functional MR. Maurice Sarano has shown that even mod-
erate MR has a deleterious influence on survival when LV function
is altered. Therefore, I think you should select the patients who are
absolutely inoperable, because you leavemost of themwith a grade
2 MR, which is again not innocuous in a bad ventricle.
My second point is that you say the mortality is approximately
1%. But we have heard that it can increase to 18% when a patient
has to undergo reoperation after a failed clip.
Dr Treede. We are absolutely of your opinion, and we would
still only include patients in the MitraClip program who are at
high risk for surgery but probably not completely inoperable, be-
cause inoperability has another aspect. Once you have done the
MitraClip placement and see an increase in MR, then you should
probably have a way to treat the patients afterward. If the patients
are completely inoperable, it is hard to include them in the program
because we would no longer have an exit strategy for a patient in
whom the clip has failed or even does harm to the valve.
The 2 patients dying after surgery because of failed implanta-
tion died in an outside hospital. It is hard for us to judge if that
was due to surgeons who did not have much experience with mi-
tral valve operations. I would definitely suggest and strongly rec-
ommend that only very experienced mitral valve surgeons
perform reoperations in patients after the clip. So this is at least
something we would recommend. I don’t think that 18% is the
true mortality for patients undergoing surgery after clip
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